CN
O0150000
应用筛选条件
关键词:'O0150000'
显示 1-30 共 111 条结果 关于 "O0150000" 范围 论文
Drugs in R&D, 5(6), 349-350 (2004-11-26)
Santarus Inc. is developing an immediate-release formulation of omeprazole in combination with an antacid (sodium bicarbonate) as a powder for suspension, known as Acitreltrade mark [SAN 05] and also as Rapinex powder for oral suspension. This omeprazole powder suspension will
Richard T Addo et al.
AAPS PharmSciTech, 16(1), 30-34 (2014-08-28)
Proton pump inhibitors (PPIs) are used extensively for the relief of gastroesophageal reflux, peptic ulcers, and other hypersecretory conditions. Some of the commonly used PPIs-omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole-were used in this study with the aim of developing a
Maria Jose Solana et al.
European journal of clinical pharmacology, 66(4), 323-330 (2009-12-31)
The proton pump inhibitors are first-line drugs for the treatment of a number of gastrointestinal diseases. These drugs have a good safety profile, making it possible to use them in paediatric patients. Although their pharmacokinetics in children has not been
Matthew H Thompson et al.
Journal of the Royal Army Medical Corps, 159(2), 126-128 (2013-05-31)
We present a case of a 27-year-old Royal Marine with a massive pericardial effusion, presenting with minimal clinical findings, suggesting that high levels of physical fitness may effectively mask the normal symptoms of this potentially life-threatening condition.
Sarah K Lawrence et al.
Drug metabolism and disposition: the biological fate of chemicals, 42(7), 1180-1190 (2014-04-22)
Dabrafenib is a potent ATP-competitive inhibitor for the V600 mutant b-rapidly accelerated fibrosarcoma (b-raf) kinase currently approved in the United States for the treatment of metastatic melanoma. Studies were conducted in human liver microsomes, recombinant human cytochrome P450 (P450) enzymes
[Comment of the Delphi Care editors on Critical evaluation of interaction screening software available in pharmacies].
Daniel Duh et al.
Journal de pharmacie de Belgique, (4)(4), 14-15 (2013-01-29)
[Using ursodez in the treatment of refractory form of gastroesophageal reflux disease].
A M Osadchuk et al.
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, (4)(4), 74-75 (2013-02-14)
Kazuhiro Shiizaki et al.
Molecular pharmacology, 85(2), 279-289 (2013-11-23)
Omeprazole (OME) induces the expression of genes encoding drug-metabolizing enzymes, such as CYP1A1, via activation of the aryl hydrocarbon receptor (AhR) both in vivo and in vitro. However, the precise mechanism of OME-mediated AhR activation is still under investigation. While
Yoshikazu Kinoshita et al.
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 110(2), 234-242 (2013-02-06)
Efficacy of esomeprazole 40mg/day (E40) and 20mg/day (E20) as initial treatment for reflux esophagitis (RE) was compared with omeprazole 20mg/day (O20) in this multicenter, prospective, randomized, double-blind study. Healing rates at week 8 (primary endpoint) were 90.0% (171/190), 87.3% (165/189)
Yehia El-Garem et al.
Urology, 84(6), 1347-1350 (2014-11-30)
To assess the effect of treatment of seminal Helicobacter pylori in infertile asthenozoospermic men. In all, 223 infertile asthenozoospermic men were consecutively selected. They were subjected to history taking, clinical examination, semen analysis, and estimation of H pylori IgA antibodies
Vaibhav Mishra et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 20(6), 506-511 (2013-03-07)
In continuation of our drug discovery program on Indian medicinal plants, the gastro protective mechanism of chebulinic acid isolated from Terminalia chebula fruit was investigated. Chebulinic acid was evaluated against cold restraint (CRU), aspirin (AS), alcohol (AL) and pyloric ligation
OTC omeprazole for your heartburn--enormous value-for-money opportunity.
Frederic R Curtiss
Journal of managed care pharmacy : JMCP, 10(5), 458-460 (2004-09-17)
Donald Castell
Expert opinion on pharmacotherapy, 6(14), 2501-2510 (2005-11-02)
Immediate-release omeprazole (Zegerid, Santarus) is the first immediate-release oral proton pump inhibitor to reach the market. As a powder formulation for oral suspension, it is indicated for the treatment of gastroesophageal reflux disease, erosive oesophagitis, duodenal ulcer and gastric ulcer
J Labenz et al.
MMW Fortschritte der Medizin, 154 Suppl 4, 110-114 (2013-01-19)
Heartburn and acid regurgitation--cardinal symptoms of gastro-esophageal reflux disease (GERD)--rank among the most frequent gastrointestinal disorders. The high degree of suffering often requires a fast and effective symptom relief. Proton pump inhibitors (PPI) are the medication of choice for all
K O Dvorshchenko et al.
Ukrains'kyi biokhimichnyi zhurnal (1999 ), 85(5), 114-123 (2014-02-01)
Free-radical processes upon long-term omeprazole-induced gastric hypochlorhydria in the rat liver were researched. Intensification of oxidative processes in the liver tissue upon gastric hypoacid state was established: overproduction of superoxide anion, hydrogen peroxide, the quantitative changes of lipid functional groups
Avnesh S Thakor et al.
The Australasian journal of dermatology, 50(3), 207-210 (2009-08-08)
Worldwide, proton pump inhibitors (PPI) are one of the most frequently prescribed drugs; however, up to 70% of patients taking these drugs have no appropriate indication. Although PPI are relatively well tolerated, they are not free from side-effects and several
Srikumar Sengupta et al.
Toxicological sciences : an official journal of the Society of Toxicology, 140(1), 236-245 (2014-04-23)
Early phase drug development relies on primary human hepatocytes for studies of drug metabolism, cytotoxicity, and drug-drug interactions. However, primary human hepatocytes rapidly lose metabolic functions ex vivo and are refractory to expansion in culture and thus are limited in
Rohan K Mahabaleshwarkar et al.
Current medical research and opinion, 29(4), 315-323 (2013-02-01)
To examine the effect of concomitant use of clopidogrel and PPIs in a national sample of elderly Medicare beneficiaries (age ≥65 years). A nested case-control design was employed. A cohort of Medicare beneficiaries who initiated clopidogrel and did not have
Julia Dinger et al.
Analytical and bioanalytical chemistry, 406(18), 4453-4464 (2014-05-17)
Knowledge about the cytochrome P450 (CYP) inhibition potential of new drug candidates is important for drug development because of its risk of interactions. For novel psychoactive substances (NPS), corresponding data are not available. For developing a general drug inhibition cocktail
Clara Rosso-Fernández et al.
Trials, 16, 102-102 (2015-04-16)
Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment
Rym Chioukh et al.
Drug metabolism and disposition: the biological fate of chemicals, 42(12), 2041-2048 (2014-09-23)
The coadministration of methotrexate (MTX) and proton pump inhibitors (PPIs) can result in a pharmacokinetic interaction that delays MTX elimination and subsequently increases the MTX blood concentrations. Human organic anion transporters (hOATs) are responsible for the renal tubular secretion of
Luigi Dall'Olmo et al.
PloS one, 9(11), e112862-e112862 (2014-11-22)
Chronic gastro-duodenal reflux in the esophagus is a major risk for intestinal metaplasia and Barrett's adenocarcinoma. A role for chronic use of proton pump inhibitor (PPI) in the increased incidence of esophageal adenocarcinoma in Western countries has been previously suggested.
N Inui et al.
Clinical pharmacology and therapeutics, 94(6), 702-708 (2013-08-27)
Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A are major factors involved in the metabolism of clinically prescribed drugs. Because the time course after drug treatment discontinuation has received little attention, we aimed to clarify the chronological changes of
M T Ventura et al.
Journal of biological regulators and homeostatic agents, 27(2), 589-594 (2013-07-09)
Corticosteroids are therapeutic drugs widely used in cases of allergic, inflammatory and autoimmune diseases, but sometimes allergic hypersensitivity reactions have been reported as a rare adverse effect of the corticosteroids themselves. Moreover, glucocorticoids can induce gastric lesions; thats why they
Andrew Curtright et al.
PloS one, 10(1), e0116766-e0116766 (2015-01-15)
Acute and chronic pain conditions are often debilitating, inflicting severe physiological, emotional and economic costs and affect a large percentage of the global population. However, the development of therapeutic analgesic agents based primarily on targeted drug development has been largely
Yasuhiro Uno et al.
Biochemical pharmacology, 91(2), 242-248 (2014-07-19)
CYP2C19 (formerly known as CYP2C75), highly homologous to human CYP2C19, has been identified in cynomolgus and rhesus macaques, non-human primate species widely used in drug metabolism studies. CYP2C19 is predominantly expressed in liver and encodes a functional drug-metabolizing enzyme. Genetic
Lassina Badolo et al.
Xenobiotica; the fate of foreign compounds in biological systems, 45(2), 177-187 (2014-09-04)
1. Regulation of hepatic metabolism or transport may lead to increase in drug clearance and compromise efficacy or safety. In this study, cryopreserved human hepatocytes were used to assess the effect of 309 compounds on the activity and mRNA expression
I B Angotoeva et al.
Vestnik otorinolaringologii, (3)(3), 52-55 (2013-07-28)
The objective of the present study was to attract attention of practitioners to the possibility of involvement of pharyngel tonsils in the pathological process in the patients presenting with gastroesophageal reflux. Two clinical cases are reported to illustrate the possibility
Nicholas I Cutfield et al.
The New Zealand dental journal, 108(4), 140-147 (2013-03-13)
To provide information about the most common medications listed as being taken by dental patients presenting to an outpatient setting at a tertiary institution and to establish a list of the most common medications for review for the general dental
Paul A Gurbel et al.
American heart journal, 165(2), 176-182 (2013-01-29)
A common regimen for patients requiring dual-antiplatelet therapy who are at risk for gastrointestinal complications is the synchronous administration of enteric-coated (EC) aspirin, a proton pump inhibitor, and clopidogrel, although proton pump inhibitors have the potential for pharmacodynamic interaction with
1/4